Assessment of COVID-19 vaccine effectiveness against Delta variant: A case-control study in the United Kingdom”
A recent study published in BMC Infectious Diseases investigated the effectiveness of COVID-19 vaccines against the Delta variant in the United Kingdom. The study, titled “Assessment of COVID-19 vaccine effectiveness against Delta variant: A case-control study in the United Kingdom,” analyzed data from a case-control study involving individuals infected with the Delta variant and a control group of uninfected individuals. The findings revealed that two doses of the Pfizer-BioNTech vaccine were highly effective in preventing symptomatic disease caused by the Delta variant, with an estimated effectiveness of 88%. Similarly, two doses of the AstraZeneca vaccine were found to have an effectiveness of 67%. The study also highlighted the importance of receiving both vaccine doses to achieve optimal protection. However, the effectiveness of a single dose was significantly lower, emphasizing the need for complete vaccination. These findings contribute valuable insights to our understanding of vaccine effectiveness against the Delta variant and support the ongoing efforts to control the spread of COVID-19.